The Technical Analyst
CorMedix Inc [CRMD]
Exchange: AMEX Industry: Biotechnology
CorMedix Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
2.32% $5.29
America/New_York / 13 mai 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 290.85 mill |
| EPS: | -0.910 |
| P/E: | -5.81 |
| Earnings Date: | Aug 06, 2024 |
| SharesOutstanding: | 54.98 mill |
| Avg Daily Volume: | 0.642 mill |
| RATING 2024-05-13 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.81 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.81 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.846 (-84.01%) $-4.44 |
| Date: 2024-05-13 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.82 - 5.71 ( +/- 8.42%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-05 | Lefkowitz Steven W | Buy | 30 000 | Stock Option (Right to Buy Common Stock) |
| 2024-03-05 | Stewart Robert A | Buy | 30 000 | Stock Option (Right to Buy Common Stock) |
| 2024-03-05 | Kaplan Myron | Buy | 30 000 | Stock Option (Right to Buy Common Stock) |
| 2024-03-05 | Dillione Janet | Buy | 30 000 | Stock Option (Right to Buy Common Stock) |
| 2024-03-05 | Dunton Alan W | Buy | 30 000 | Stock Option (Right to Buy Common Stock) |
| INSIDER POWER |
|---|
| 93.13 |
| Last 95 transactions |
| Buy: 4 530 513 | Sell: 123 432 |
Forecast:
16:00 - $5.29
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.29
Forecast 2: 16:00 - $5.29
Forecast 3: 16:00 - $5.29
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.29 (2.32% ) |
| Volume | 0.382 mill |
| Avg. Vol. | 0.642 mill |
| % of Avg. Vol | 59.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CRMD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $3.01 | N/A | Active |
|---|
CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Latest Press Releases
2024-05-10 08:30:00 - Press Release
Cormedix Inc. To Participate In Two Upcoming Investor Conferences
Berkeley heights, n.j., may 10, 2024 (globe newswire) -- cormedix inc. (nasdaq: crmd), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in fireside chats and investor meetings at both the jmp securities life sciences conference being held in new york on may 13 – 14, 2024 and the 2024 rbc capital markets global healthcare conference being held in new york on may 14 – 15, 2024. details for each fireside chat are as follows:
2024-05-09 07:30:00 - Press Release
Cormedix Inc. Reports First Quarter 2024 Financial Results And Provides Business Update
Berkeley heights, n.j., may 09, 2024 (globe newswire) -- cormedix inc. (nasdaq: crmd), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended march 31, 2024 and provided an update on its business.
2024-05-06 08:30:00 - Press Release
Cormedix Inc. To Report First Quarter 2024 Financial Results And Provide A Corporate Update On May 9, 2024
Berkeley heights, n.j., may 06, 2024 (globe newswire) -- cormedix inc. (nasdaq: crmd), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended march 31, 2024, before the market opens on thursday, may 9, 2024, and will host a corporate update conference call at 8:30am eastern time.
2024-04-19 08:30:00 - Press Release
Cormedix Inc. Announces Cms Grants Tdapa To Defencath
Berkeley heights, n.j., april 19, 2024 (globe newswire) -- cormedix inc. (nasdaq: crmd), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the center for medicare & medicaid services (cms) has determined that defencath® meets the criteria for a transitional drug add-on payment (tdapa) in the anti-infective functional category, beginning on july 1, 2024. the tdapa program currently provides for five years of additional payment reimbursement beyond the esrd bundled rate to outpatient providers, and aligns with cormedix's upcoming outpatient launch in july.
2024-04-15 08:30:00 - Press Release
Cormedix Inc. Announces U.s. Inpatient Commercial Availability Of Defencath® (taurolidine And Heparin)
Berkeley heights, n.j., april 15, 2024 (globe newswire) -- cormedix inc. (nasdaq: crmd), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced defencath® (taurolidine and heparin) catheter lock solution (cls) is now commercially available for u.s. inpatient use.
Latest News
2024-05-11 17:48:08 - Seeking Alpha
CorMedix Inc. (CRMD) Q1 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Joe Todisco - Chief Executive Officer Matt David - EVPr and CFO Beth Zelnick Kaufman - EVP and Chief Legal Officer Liz Hurlburt - EVP and Chief Clinical Strategy and Operations Officer Erin Mistry - EVP and Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Operator Good morning, and welcome to the CorMedix First Quarter 2024 Earnings Conference Call [Operator Instructions]. Today's conference call is being recorded.
2024-05-10 08:30:00 - GlobeNewsWire
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York on May 14 – 15, 2024. Details for each fireside chat are as follows:
2024-05-06 08:30:00 - GlobeNewsWire
CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024
BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2024, before the market opens on Thursday, May 9, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
2024-05-02 10:55:20 - Zacks Investment Research
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
The mean of analysts' price targets for CorMedix (CRMD) points to a 135.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-04-15 12:54:18 - InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
2024-04-11 10:55:24 - Zacks Investment Research
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
The mean of analysts' price targets for CorMedix (CRMD) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-03-12 11:17:03 - Seeking Alpha
CorMedix (CRMD) Q4 2023 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financial Officer Erin Mistry - Executive Vice President, Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Dan Ferry - LifeSci Advisors Conference Call Participants Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Lew Sulewski - Truist Securities Serge Belanger - Needham & Co. Operator Good morning ladies and gentlemen, and welcome to the CorMedix Inc. fourth quarter and full year 2023 earnings call. At this time, all lines are in a listen-only mode.
2024-03-06 08:30:00 - GlobeNewsWire
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
2023-11-15 10:11:20 - Reuters
U.S. FDA approves CorMedix's antimicrobial drug
The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, the regulator said.
2023-11-14 21:55:11 - Seeking Alpha
CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - CEO Matt David - EVP and CFO Phoebe Mounts - EVP and General Counsel Conference Call Participants Jason Butler - JMP Securities Leszek Sulewski - Truist Securities Gregory Renza - RBC Capital Markets Operator Good afternoon, and welcome to CorMedix Third Quarter 2023 Earnings Conference Call. Today's call is being recorded.